Publication
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerThyroid Gland Medullary Carcinomacivic_curation1.00
- drugSelpercatinibcivic_curation1.00
- geneRETcivic_curation1.00
- variantRET M918Tcivic_curation1.00
- variantRET Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37870969
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RET M918T1 | ||||||||
| Selpercatinib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12598The Phase 3 trial for the selective and brain-penetrant RET kinase inhibitor selpercatinib in Medullary Thyroid Cancer (MTC) LIBRETTO-531 (NCT04211337) consisted of 291 total patients. The patients … (full text at CIViC) PMID 37870969 · Hadoux et al., 2023 · Open in CIViC | civic |
| RET Mutation1 | ||||||||
| Selpercatinib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12157In this phase III trial, 291 patients (12 years or older) with medullary thyroid cancer harbouring RET mutations were enrolled. Patients were randomized in a 2:1 ratio to receive selpercatinib (n=193)… (full text at CIViC) PMID 37870969 · Hadoux et al., 2023 · Open in CIViC | civic |